Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo

The fibrotic tumor stroma

(2018) Mitsuo Yamauchi et al.   JOURNAL OF CLINICAL INVESTIGATION

Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors

(2017) Miroslava Didiasova et al.   FASEB JOURNAL

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

(2017) Federica Grosso et al.   JOURNAL OF CLINICAL ONCOLOGY

Pirfenidone Induces G1 Arrest in Human Tenon's Fibroblasts In Vitro Involving AKT and MAPK Signaling Pathways

(2017) Xiujuan Guo et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer

(2017) Ayako Fujiwara et al.   LUNG CANCER

Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis

(2017) Zhenzhen Li et al.   NEPHROLOGY

The Reactome Pathway Knowledgebase

(2017) Antonio Fabregat et al.   NUCLEIC ACIDS RESEARCH

Gremlin-1 is a key regulator of the invasive cell phenotype in mesothelioma

(2017) Miao Yin et al.   Oncotarget

Pirfenidone normalizes the tumor microenvironment to improve chemotherapy

(2017) Christiana Polydorou et al.   Oncotarget

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

(2016) Melanie Mediavilla-Varela et al.   BMC CANCER

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study

(2016) Mir Alireza Hoda et al.   EUROPEAN JOURNAL OF CANCER

Non-Smad Signaling Pathways of the TGF-β Family

(2016) Ying E. Zhang   Cold Spring Harbor Perspectives in Biology

Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer

(2016) Ken Takai et al.   Oncotarget

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma

(2015) T. Yamada et al.   CANCER RESEARCH

Overexpression of activin-A and -B in malignant mesothelioma – Attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth

(2015) Jenni A. Tamminen et al.   EXPERIMENTAL CELL RESEARCH

Role and New Insights of Pirfenidone in Fibrotic Diseases

(2015) David Alejandro Lopez-de la Mora et al.   International Journal of Medical Sciences

Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

(2014) Aurélien de Reyniès et al.   CLINICAL CANCER RESEARCH

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

(2014) Enrico Conte et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

(2014) Yoshito Takeda et al.   Patient Preference and Adherence

New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas

(2013) Brooke T. Mossman et al.   AMERICAN JOURNAL OF PATHOLOGY

Cyclic Adenosine Monophosphate-Response Element–Binding Protein Mediates the Proangiogenic or Proinflammatory Activity of Gremlin

(2013) Michela Corsini et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate Cells

(2013) S. Kozono et al.   CANCER RESEARCH

Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug

(2013) J A Tamminen et al.   Oncogenesis

Bone Morphogenetic Protein–Inducer Tilorone Identified by High-Throughput Screening Is AntifibroticIn Vivo

(2012) Outi Leppäranta et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group

(2012) Aliya N. Husain et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma

(2012) Roberto E Favoni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antifibrotic Effects of Pirfenidone in Rat Proximal Tubular Epithelial Cells

(2012) Koji Takakura et al.   RENAL FAILURE

Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome

(2012) Marija Milacic et al.   Cancers

Non-Smad signaling pathways

(2011) Yabing Mu et al.   CELL AND TISSUE RESEARCH

Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases

(2010) Sonja Klebe et al.   MODERN PATHOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells

(2009) Yoshitaka Sekido   CANCER SCIENCE

Genomic events associated with progression of pleural malignant mesothelioma

(2008) Sergey V. Ivanov et al.   INTERNATIONAL JOURNAL OF CANCER

Gremlin-mediated Decrease in Bone Morphogenetic Protein Signaling Promotes Pulmonary Fibrosis

(2007) Marjukka Myllärniemi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE